Correlation Between the SPhENo-Cardiograph™, a Seismocardiograph Device, and GE Vivid Q, an Echocardiograph, for Known Systemic Timing Intervals (STI)

Cardiovascular Risk Factor Clinical Trial

Official title:

A Clinical Study to Determine the Correlation Between the SPhENo-Cardiograph™, a Seismocardiograph Device, and GE Vivid Q, an Echocardiograph, for Known Systemic Timing Intervals (STI).

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02636023
• Other study ID #: SPHENO_CLIN_003
• Status: Completed
• Phase: N/A
• First received: October 22, 2015
• Last updated: February 10, 2016
• Start date: August 2015
• Est. completion date: August 2015

Study information

• Verified date: February 2016
• Source: Heart Force Medical Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The study Sponsor, Heart Force Medical Inc. (HFM), has developed a patented medical device called the SPhENo-CardiographTM. The SPhENo-Cardiograph™ provides a non-invasive assessment of the electro-mechanical function of the heart. The electrocardiograph (ECG) represents the waveform of the electrical stimulus to the cardiac muscle. The mechanical actions of the electrical potentials delivered in the ECG are revealed as the seismocardiograph (SCG). The SCG represents the changes in acceleration of the heart during the cardiac cycle. The SCG waveform reflects the ultra-low frequency vibrations of cardiac contraction. These low frequency vibrations are transmitted through the sternum. Using the point of initiation of ventricular contraction on the ECG, the Q wave, with fiduciary points on the synchronous seismocardiograph, it is possible to determine timing events of the cardiac cycle. The timing events of the cardiac cycle during systole are referred to as Systolic Timing Intervals (STI) and comprise the Pre-Ejection Period (PEP) and the Left Ventricular Ejection Time (LVET). The PEP is the time from the Q wave to the Aortic valve opening. The Left Ventricular Eject Time (LVET) is the time between the Aortic Valve opening and closing. The ratio of PEP/LVET in individuals with established heart disease is > 0.42. It is based on the formula described by Dr Arnold Weissler and first published in Circulation in 1968 (Weissler et al,1968). Weissler et al showed that the PEP/LVET ratio >0.42 are indicative of a lengthening of the PEP with some marginal shortening of the LVET. This is indicative of pathology associated with the coronary circulation (Ahmed et al, 1972;). This ratio can then be used as part of a non-invasive quantitative assessment of cardiac performance (Lewis et al 1977).

Using the SPhENo-CardiographTM, HFM has developed an algorithm to assess heart health that otherwise requires a number of technologies; stethoscope, ECG and Carotid pulse tracing to identify the dicrotic notch or Aortic Valve closure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Able to understand the informed consent document

• Willing to participate in study

• Ambulatory volunteer

Exclusion Criteria:

• Individuals with visible scar(s) or deformity in the test area of the chest

• Non-ambulatory subjects

• Previously diagnosed with life-threatening condition (e.g. cancer)

• Known or diagnosed psychiatric condition

• Enrolled in a concurrent study or trial

• Exercised excessively within the last 4 hours (prior to study visit)

• Consumption of caffeine containing drinks within the previous 4 hours

• Unwilling to sign Informed Consent

• Female subjects who are pregnant, suspected or planning to become pregnant or breast-feeding

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Cardiovascular Risk Factor

Intervention

Device:
• SPhENo-Cardiograph
SPhENo-Cardiograph

Locations

Country	Name	City	State
Canada	Boucher Institute of Naturopathic Medicine	New Westminster	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Heart Force Medical Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation coefficient =0.8 between STI ratio values determined by the SPhENo-Cardiograph™ and an echocardiograph		1 day	No
Primary	Correlation coefficient =0.8 between PEP values determined by the SPhENo-Cardiograph™ and an echocardiograph		1 day	No
Primary	Correlation coefficient =0.8 between LVET values determined by the SPhENo-Cardiograph™ and an echocardiograph		1 day	No
Primary	Correlation coefficient =0.8 between heart rate values determined by the SPhENo-Cardiograph™ and an echocardiograph		1 day	No
Secondary	Correlation coefficient =0.8 between STI ratio values determined by the SPhENo-Cardiograph™ and a manual analysis		1 day	No
Secondary	Correlation coefficient =0.8 between PEP values determined by the SPhENo-Cardiograph™ and a manual analysis		1 day	No
Secondary	Correlation coefficient =0.8 between LVET values determined by the SPhENo-Cardiograph™ and a manual analysis		1 day	No
Secondary	Correlation coefficient =0.8 between heart rate values determined by the SPhENo-Cardiograph™ and a manual analysis		1 day	No
Secondary	Safety and tolerability assessed by Adverse event collection	Adverse event collection	1 day	Yes
Secondary	Subject questionnaire	Questionnaire to evaluate relevance of device from subject's perspective; data to be analyzed qualitatively	1 day	No